30 October 2025 in International Journal of Pharmacology
Oxidative stress and inflammation are widely recognized as key mechanisms in the pathogenesis of Drug-Induced Liver Injury (DILI). Meanwhile, preclinical studies have demonstrated that tocotrienols (T3s), members of the vitamin E family, possess significant antioxidant and anti-inflammatory properties, suggesting a potential hepatoprotective role in various liver disorders. Clinical trials investigating Non-Alcoholic Fatty Liver Disease (NAFLD), a condition that shares important pathophysiological features with DILI, have also reported favorable outcomes associated with T3 supplementation. Notably, the overlap between the established mechanisms of T3s and the underlying pathophysiology of DILI provides a strong rationale for exploring the therapeutic potential of T3s in this context. Emerging evidence from studies on NAFLD further supports this approach, considering the common mechanistic pathways involved. Accordingly, this review aims to comprehensively evaluate current preclinical and clinical evidence on T3s in relation to DILI, elucidate the proposed mechanisms of action of this class of vitamin E analog, and identify key gaps in the literature that warrant further investigation.
28 October 2026 in Journal of Drug Delivery Science and Technology
28 April 2026 in SSRN Electronic Journal
Peptide-based cancer vaccines offer high antigen specificity but are frequently limited by rapid degradation, inefficient delivery, and insufficient immune priming, particularly due to tumor antigen heterogeneity. To address these challenges, we developed a biomimetic liposomal nanovaccine that integrates defined HER2-derived peptide epitopes with native tumor antigens through cancer cell membrane (CCM) functionalization. A HER2-derived multi-epitope peptide comprising cytotoxic T-lymphocyte and B-cell epitopes, conjugated to keyhole limpet hemocyanin (KLH), was encapsulated within liposomes, followed by surface coating with CCM to reconstruct a tumor-mimetic nano–bio interface for enhanced immune recognition. The nanovaccine formulation was optimized for peptide encapsulation efficiency, membrane coating integrity, and particle size distribution. In vivo immunization studies in BALB/c mice demonstrated that CCM-coated liposomal nanovaccines elicited significantly enhanced HER2-specific humoral and cellular immune responses, including elevated IgG titers, increased splenocyte proliferation, and augmented IFN-γ secretion, without inducing reactogenicity or excessive inflammatory responses. Importantly, prophylactic efficacy was strongly influenced by the source of the CCM, with antigen-matched membranes producing superior tumor growth suppression and prolonged survival compared with mismatched membrane coatings in a HER2-positive breast cancer challenge model. Overall, this study demonstrates that rational integration of well-defined HER2 peptide epitopes with homologous CCM antigens within a single liposomal delivery system can substantially enhance immune priming and prophylactic efficacy. These findings highlight the critical role of membrane source selection in biomimetic nanovaccine design and provide a conceptual avenue toward personalized cancer vaccination, wherein CCM may be sourced from individual tumors to tailor antigenic presentation.